| House of Representatives Standing Committee on Health and Ageing

Footnotes

Chapter 1 Introduction

[1]       P Day, Arachnoiditis: A brief summary of the literature, (2001) New Zealand Health Technology Assessment, pp. 7-9.

[2]       In the UK Myodil was produced by Glaxo (now GlaxoSmithKline) and in the USA Pantopaque was produced by Lafayette Pharmacal.

[3]       Commonwealth, Parliamentary Debates, House of Representatives, 19 September 2011, 10707 (Steve Irons).

[4]       See: Commonwealth, Parliamentary Debates, House of Representatives, 16 September 2002, 6267 (Jennie George); Commonwealth, Parliamentary Debates, House of Representatives, 16 September 2002, 6270 (Mal Washer); and Commonwealth, Parliamentary Debates, House of Representatives, 16 September 2002, 6273 (Andrew Southcott).

[5]       See: Commonwealth, Parliamentary Debates, House of Representatives, 16 September 2002, 6267 (Jennie George); Commonwealth, Parliamentary Debates, House of Representatives, 16 September 2002, 6270 (Mal Washer); and Commonwealth, Parliamentary Debates, House of Representatives, 16 September 2002, 6273 (Andrew Southcott).

[6]       The Committee has a general power to inquire into the annual reports of Commonwealth agencies under Standing Order 215(c).

[7]       Correspondence to the Standing Committee on Health and Ageing from GlaxoSmithKline, dated 12 October 2012.

Chapter 2 Issues and conclusions

[1]       Professor Marcus Stoodley, Official Committee Hansard, Canberra, 21 September 2012, p. 2.

[2]       Professor Marcus Stoodley and Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, pp. 2, 6.

[3]       Mrs Maureen McLean, AASA, Official Committee Hansard, Canberra, 21 September 2012, p. 12; Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 7.

[4]       Professor Marcus Stoodley, Official Committee Hansard, Canberra, 21 September 2012, p. 3.

[5]       Professor Marcus Stoodley, Official Committee Hansard, Canberra, 21 September 2012, p. 3.

[6]       M D M Shaw, J A Russell, K W Grossart, ‘The changing pattern of spinal arachnoiditis,’ Journal of Neurology, Neurosurgery and Psychiatry, 1978, vol 41, pp. 97-107.

[7]       The Hon Kevin Andrews MP, Minister representing the Minister for Health and Ageing, House of Representatives Hansard, 14 May 2003, p. 14,594.

[8]       Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[9]       Professor Marcus Stoodley, Official Committee Hansard, Canberra, 21 September 2012, p. 2.

[10]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[11]     W Ward, M Matheson, A Gonski, ‘Three Cases of Granulomatous Arachnoiditis after Myelography,’ Medical Journal of Australia, 28 August 1976, vol 2(9), p. 335.

[12]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[13]     F L Davies, ‘Effect of Unabsorbed Radiographic Contrast Media on the Central Nervous System,’ The Lancet, 13 October 1956, pp. 747-48.

[14]     G F Swann, ‘Technique of Positive Contrast Myelography,’ Proceedings of the Royal Society of Medicine, June 1960, vol 53(6), pp. 448-54.

[15]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, pp. 13-14.

[16]     W J Howland, J L Curry, A K Butler, ‘Pantopaque Arachnoiditis: Experimental Study of Blood as a Potentiating Agent,’ Radiology, March 1963, vol 80(3), pp. 489-91.

[17]     W J Howland, J L Curry, ‘Experimental Studies of Pantopaque Arachnoiditis,’ Radiology, August 1966, vol 87(2), pp. 253-60.

[18]     Correspondence dated 14 April 1969 from the Food and Drug Administration to Lafayette Pharmacal, viewed 12 November 2012 at <http://www.myodilaction.info/fda_warning_1969.html>.

[19]     Correspondence to the Standing Committee on Health and Ageing from GSK, dated 12 October 2012.

[20]     Correspondence to the Standing Committee on Health and Ageing from GSK, dated 12 October 2012.

[21]     For example, J Jorgensen, P H Hansen, V Steenskov, N Ovesen, ‘A Clinical and Radiological Study of Chronic Lower Spinal Arachnoiditis,’ Neuradiology, 1975, vol 9, pp. 139-44.

[22]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 11.

[23]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 15.

[24]     W Ward, M Matheson, A Gonski, ‘Three Cases of Granulomatous Arachnoiditis after Myelography,’ Medical Journal of Australia, 28 August 1976, vol 2(9), pp. 333-35.

[25]     Dr Anthony Gill, Therapeutic Goods Administration (TGA), Official Committee Hansard, Canberra, 21 September 2012, p. 11.

[26]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[27]     M R Sage, G T Benness, L V Perrett, J Mansfield, ‘Lumbar myelography today. Experience with metrizamide, a water-soluble, non-ionic contrast medium.’ Medical Journal of Australia, 21 February 1981, pp. 175-76.

[28]     C C McCormick, H T ApSimon and T M Chakera, ‘Myelography with Merizamide – An Analysis of the Complications Encountered in Cervical, Thoracic and Lumbar Myelography,’ Australian and New Zealand Journal of Medicine, October 1981, vol 11(5), pp. 645-50.

[29]     Professor Marcus Stoodley, Official Committee Hansard, Canberra, 21 September 2012, p. 2.

[30]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 11.

[31]     Dr Anthony Gill, TGA, Official Committee Hansard, Canberra, 21 September 2012, p. 10; D. Brahams, ‘UK Myodil arachnoiditis claims settled out of court,’ The Lancet, 5 August 1995, vol. 346(8971), p. 368; The Hon Kevin Andrews MP, Minister representing the Minister for Health and Ageing, House of Representatives Hansard, 14 May 2003, p. 14,594.

[32]     Correspondence to the Standing Committee on Health and Ageing from GSK, dated 12 October 2012.

[33]     The Hon Kevin Andrews MP, Minister representing the Minister for Health and Ageing, House of Representatives Hansard, 14 May 2003, p. 14,594.

[34]     Australian Audit Office, Report of the Auditor-General upon audits, examinations and inspections under the Audit and Other Acts, March 1984, pp. 96-99.

[35]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[36]     M E Wood v Glaxo Australia P/L, Supreme Court of Queensland, J Cooper, 33 of 1990, 28 February 1992, BC9202281, p. 18.

[37]     The case cited C V Burton, ‘Adhesive Arachnoiditis,’ 1990, Ch. 97, pp. 2859-61, in J Youmans (ed), Neurological Surgery, 3^rd edn, Philadelphia: W B Saunders.

[38]     Correspondence from the Swedish Medical Products Agency to Glaxo Research Group Ltd, 16 July 1993, provided to the Standing Committee on Health and Ageing by GSK.

[39]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 15.

[40]     Correspondence to the Standing Committee on Health and Ageing from GSK, dated 12 October 2012.

[41]     D Brahams, ‘UK Myodil arachnoiditis claims settled out of court,’ The Lancet, 5 August 1995, vol. 346(8971), p. 368. See also: E Jellinek, ‘Myodil arachnoiditis: Iatrogenic and forensic illness,’ Practical Neurology, August 2002, vol 2, pp. 237-39.

[42]     M E Wood v Glaxo Australia P/L, Supreme Court of Queensland, J Cooper, 28 February 1992,  33 of 1990, BC9202281; M E Wood v Glaxo Australia P/L, Supreme Court of Queensland – Court of Appeal, C J Macrossan, J Davies, J Ambrose, 30 March 1993, 37 of 1992. Glaxo Australia P/L v M E Wood, High Court of Australia, J Toohey, J Gaudron, J McHugh, 2 July 1993, B18 of 1993. The High Court did not give detailed reasons for refusing special leave. It simply stated that it ‘is not persuaded that the actual decision of the Court of Appeal is attended with sufficient doubt to warrant a grant of special leave to appeal.’ J Toohey at p. 22.

[43]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 23.

[44]     Commonwealth of Australia 2013 website, National Disability Insurance Scheme, viewed 4 January 2013 at <http://www.ndis.gov.au/>.

[45]     South Australia, Tasmania, ACT, the Hunter in NSW and the Barwon area of Victoria.

[46]     Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 5

[47]     Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 5.

[48]     Mr Maxwell Scott, Official Committee Hansard, Canberra, 21 September 2012, p. 13.

[49]     Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 5.

[50]     Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 5.

[51]     Mrs Maureen McLean, Australian Arachnoiditis Sufferers Association (AASA), Official Committee Hansard, Canberra, 21 September 2012, p. 11.

[52]     Ms Bernadette Clarke, Official Committee Hansard, Canberra, 21 September 2012, p. 20.

[53]     Mrs Maureen McLean, AASA, Official Committee Hansard, Canberra, 21 September 2012, p. 20.

[54]     Mrs Maureen McLean, AASA, Official Committee Hansard, Canberra, 21 September 2012, p. 19.

[55]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 22.

[56]     Professor Christoper Baggoley, Australian Government Department of Health and Ageing, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[57]     Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 6.

[58]     Professor Christoper Baggoley, Australian Government Department of Health and Ageing, Official Committee Hansard, Canberra, 21 September 2012, p. 24.

[59]     Professor Michael Cousins, Official Committee Hansard, Canberra, 21 September 2012, p. 7.

[60]     Mrs Ruth Ahrens, Official Committee Hansard, Canberra, 21 September 2012, p. 12.

[61]     The Hon Tanya Plibersek, Minister for Health, Media Release dated 16 November 2012, Medicine Subsidy for Sufferers of Chronic Nerve Pain. Lyrica will be listed from March 2013.

[62]     Medicare Local Perth North Metro, Self Training Educative Pain Sessions, viewed 26 November 2012 at: < http://www.pnml.com.au/index.php/Article/self-training-educative-pain-program.html>.

[63]     Professor Michael Sage, Official Committee Hansard, Canberra, 21 September 2012, p. 10.

[64]     P Day, Arachnoiditis: A brief summary of the literature, November 2001, New Zealand Health Technology Assessment Clearing House, p. vii.

Back to top